Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Requires Opioid Makers to Develop Doctor Training

By Carla K Johnson, AP Medical Writer | September 29, 2017

(Credit: AP Photo/Carla K. Johnson)

The Food and Drug Administration is requiring manufacturers of the most widely prescribed painkillers to provide extensive training to doctors in an attempt to reduce the number of patients who become addicted, and stem the ongoing opioid crisis.

The agency notified 74 manufacturers of so-called immediate-release opioids this week that their drugs will now be subject to the tougher requirements, although doctors would not be compelled to take part in the training.

The medications, which include Vicodin and Percocet, often combine oxycodone or hydrocodone with less powerful painkillers like acetaminophen. They account for 90 percent of all opioid painkillers prescribed.

Manufacturers of long-acting opioids such as OxyContin, which release their doses over 12 hours or more, have been subject to the requirements since 2012.

FDA Commissioner Scott Gottlieb called the immediate-release versions a “potential gateway to addiction” in a blog post Thursday.

About 2 million Americans are addicted to prescription opioids, and more than 15,000 died from overdoses involving prescription opioids in 2015.

Dr. Andrew Kolodny, founder of Physicians for Responsible Opioid Prescribing and an advocate for opioid reform, said the details of the trainings will be important in determining whether they have the potential to make a difference, but said Gottlieb’s choice of words is significant.

“To have the head of the FDA talk about addiction caused by medical treatment really suggests a change in what we hear about opioids,” Kolodny said.

The prescriber training, which could take a year to organize and implement, must include consideration of non-opioid alternatives.

Gottlieb wrote in the blog post that the agency’s new opioid policy steering committee is considering “whether there are circumstances when FDA should require some form of mandatory education for health care professionals, and how the agency would pursue such a goal.”

(Source: Associated Press)

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE